-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GDq0TG0/1ayFWyTnWa0qTYhLIxeW609QKYjDogLh4qzHNo3FxDWXqj522D21HHFV kt5CV2Ex7ViD+nt9KHGlow== 0001104659-08-017657.txt : 20080314 0001104659-08-017657.hdr.sgml : 20080314 20080314155127 ACCESSION NUMBER: 0001104659-08-017657 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080311 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20080314 DATE AS OF CHANGE: 20080314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 08689455 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 8-K 1 a08-8247_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant To Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 11, 2008

 

PHARMATHENE, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

One Park Place, Suite 450, Annapolis, MD

 

21401

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (410) 269-2600

 

N/A

(Former Name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 


 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(e)           Compensatory Arrangements of Certain Officers.  On March 11, 2008, the Board of Directors of PharmAthene, Inc. approved the 2008 base salary levels and 2008 annual cash bonuses for certain executive officers in accordance with the recommendations of the Company’s Compensation Committee.  The following table sets forth the annual base salary fixed for 2008 for each of the following executive officers:

 

Executive

 

Title

 

2008 Annual Base Salary

 

 

 

 

 

 

 

Eric Richman

 

Senior Vice President, Business Development

and Strategic Planning

 

$

275,126

 

Christopher C. Camut

 

Vice President, Chief Financial Officer

 

$

247,000

 

Francesca Cook

 

Vice President Policy and Government Affairs

 

$

231,612

 

Wayne Morges

 

Vice President Regulatory Affairs/ Quality Control

 

$

249,757

 

Valerie Riddle

 

Vice President Medical Director

 

$

268,425

 

 

Cash bonuses totaling, in the aggregate, $145,000 were also awarded to these executive officers.

 

                Also on March 11, 2008, in accordance with the recommendation of the Compensation Committee, our Board of Directors approved a 4% increase to the base salary of our Chief Executive Officer, David P. Wright, retroactive to January 1, 2008, bringing his base salary to $407,680 per year.

 

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

PHARMATHENE, INC.

 

 

 

 

 

 

Date: March 13, 2008

By:

/s/ David P. Wright

 

 

DAVID P. WRIGHT

 

 

Chief Executive Officer

 

 

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----